Financials BZAM Ltd.

Equities

BZAM

CA12464X1015

Pharmaceuticals

Market Closed - Canadian Securities Exchange 03:48:53 2024-04-26 pm EDT 5-day change 1st Jan Change
0.015 CAD 0.00% Intraday chart for BZAM Ltd. -50.00% -88.00%

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022
Capitalization 1 661.6 230.9 113.7 70.9 50.7
Enterprise Value (EV) 1 449.1 224.4 148.8 100.1 90.74
P/E ratio -12 x -1.06 x -0.48 x -1.24 x -0.8 x
Yield - - - - -
Capitalization / Revenue 352,080,895 x 21,077,843 x 5,287,793 x 2,344,344 x 1,027,432 x
EV / Revenue 239,015,966 x 20,476,310 x 6,921,336 x 3,309,722 x 1,838,642 x
EV / EBITDA -10.7 x -3.47 x -4.19 x -6.42 x -3.84 x
EV / FCF -3.08 x -1.18 x -1.68 x -2.59 x -2.7 x
FCF Yield -32.4% -84.9% -59.4% -38.5% -37.1%
Price to Book 1.61 x 0.87 x 0.81 x 0.52 x 0.3 x
Nbr of stocks (in thousands) 26,893 30,793 48,366 74,627 153,651
Reference price 2 24.60 7.500 2.350 0.9500 0.3300
Announcement Date 3/19/19 3/10/20 3/9/21 4/5/22 4/28/23
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales - 1.879 10.96 21.5 30.24 49.35
EBITDA 1 -14.73 -42.1 -64.73 -35.5 -15.6 -23.66
EBIT 1 -15.19 -43.16 -68.42 -41.85 -28.36 -31.57
Operating Margin - -2,296.7% -624.47% -194.68% -93.77% -63.98%
Earnings before Tax (EBT) 1 -15.01 -45.55 -196.4 -183.4 -39.98 -36.36
Net income 1 -13.46 -45.2 -195.2 -182.5 -42.14 -35.5
Net margin - -2,405.69% -1,781.1% -849.23% -139.34% -71.94%
EPS 2 -1.196 -2.055 -7.075 -4.938 -0.7632 -0.4103
Free Cash Flow 1 -5.676 -145.7 -190.6 -88.36 -38.58 -33.64
FCF margin - -7,755.1% -1,739.46% -411.06% -127.57% -68.16%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/20/18 3/19/19 3/10/20 3/9/21 4/5/22 4/28/23
1CAD in Million2CAD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1
Net sales 1 9.522 7.28 9.466 10.58 11.63 9.922 17.23 24.1
EBITDA 1 -3.995 -4.773 -3.017 -2.237 -4.274 -5.54 -16.97 -3.904
EBIT - - - - - - - -
Operating Margin - - - - - - - -
Earnings before Tax (EBT) - - - - - - - -
Net income 1 - - - - - - - -18.28
Net margin - - - - - - - -75.84%
EPS 2 - - - - - - - -0.1200
Dividend per Share - - - - - - - -
Announcement Date 8/11/21 11/24/21 4/5/22 5/25/22 8/29/22 11/23/22 4/28/23 5/30/23
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - 35.1 29.2 40
Net Cash position 1 63.7 212 6.59 - - -
Leverage (Debt/EBITDA) - - - -0.9892 x -1.871 x -1.692 x
Free Cash Flow 1 -5.68 -146 -191 -88.4 -38.6 -33.6
ROE (net income / shareholders' equity) -30.8% -18.4% -57.5% -89.9% -28.6% -23.1%
ROA (Net income/ Total Assets) -16.9% -9.94% -10.8% -9.45% -8.73% -8.42%
Assets 1 79.64 455 1,801 1,932 482.6 421.7
Book Value Per Share 2 5.420 15.30 8.570 2.900 1.840 1.090
Cash Flow per Share 2 4.470 7.910 0.8800 0.2300 0.0500 0.0300
Capex 1 6.75 81.6 220 50.3 9.12 1.12
Capex / Sales - 4,344.39% 2,004.69% 233.82% 30.16% 2.28%
Announcement Date 4/20/18 3/19/19 3/10/20 3/9/21 4/5/22 4/28/23
1CAD in Million2CAD
Estimates